Sep. 24—(StatePoint) Getting the correct treatment for bronchiectasis, a chronic lung condition affecting 350,000 to 500,000 adults nationwide, is necessary to slow disease progression and help ...
— BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed (INSM) to Host Investor ...
British scientists have found the first-ever treatment for bronchiectasis, the disease Pope Francis was hospitalized with in the weeks prior to his death, The Telegraph reported. Francis suffered from ...
CHICAGO -- Brensocatib (Brinsupri) appeared to have a disease-modifying effect on structural lung changes in non-cystic fibrosis bronchiectasis at its higher dose, a CT substudy of the ASPEN trial ...
The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...
Panelists discuss how bronchiectasis is more common than previously thought, with growing awareness, research, and specialized centers improving diagnosis and treatment options, though challenges ...
WASHINGTON, July 1, 2025 /PRNewswire/ -- Today, on World Bronchiectasis Day, the American Lung Association is launching a new campaign to support people living with bronchiectasis, which is a chronic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results